Variant ABO blood group alleles, secretor status, and risk of pancreatic cancer: Results from the pancreatic cancer cohort consortium

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 12, 2010, Pages 3140-3149

  Wolpin, Brian M ^a,b   Kraft, Peter ^c   Xu, Mousheng ^c   Steplowski, Emily ^d   Olsson, Martin L ^e   Arslan, Alan A ^f   Bueno de Mesquita, H Bas ^g,h   Gross, Myron ⁱ   Helzlsouer, Kathy ^j,k   Jacobs, Eric J ^l   LaCroix, Andrea ^m   Petersen, Gloria ⁿ   Stolzenberg Solomon, Rachael Z ^o   Zheng, Wei ^p   Albanes, Demetrius ^p   Allen, Naomi E ^q   Amundadottir, Laufey ^p,r   Austin, Melissa A ^p   Boutron Ruault, Marie Christine ^s   Buring, Julie E ^t,u   Canzian, Federico ^u   Chanock, Stephen J ^p   Gaziano, J Michael ^v   Giovannucci, Edward L ^b,c,af   Hallmans, Göran ^c   Hankinson, Susan E ^b,c   Hoover, Robert N ^p   Hunter, David J ^b,c   Hutchinson, Amy ^p,w   Jacobs, Kevin B ^p,z   Kooperberg, Charles ⁿ   Mendelsohn, Julie B ^p   Michaud, Dominique S ^c,x   Overvad, Kim ^y   Patel, Alpa V ^m   Sanchéz, Maria José ^z   Sansbury, Leah ^aa   Shu, Xiao Ou ^q   Slimani, Nadia ^ab   Tobias, Geoffrey S ^p   Trichopoulos, Dimitrios ^c,ac   Vineis, Paolo ^ad   Visvanathan, Kala ^l   Virtamo, Jarmo ^y   Wactawski Wende, Jean ^ae   Watters, Joanne ^ac   Yu, Kai ^p   Zeleniuch Jacquotte, Anne ^f,g   Hartge, Patricia ^p   Fuchs, Charles S ^a,b   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d INFORMATION MANAGEMENT SERVICES INC   (United States)

^e LUND UNIVERSITY   (Sweden)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g NEW YORK UNIVERSITY   (United States)

^h NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

ⁱ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^j UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^k MERCY MEDICAL CENTER   (United States)

^l JOHNS HOPKINS UNIVERSITY   (United States)

^m AMERICAN CANCER SOCIETY   (United States)

ⁿ Fred Hutchinson Cancer Research Center   (United States)

^o MAYO CLINIC   (United States)

^p NATIONAL INSTITUTES OF HEALTH   (United States)

^q VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^r UNIVERSITY OF OXFORD   (United Kingdom)

^s UNIVERSITY OF WASHINGTON   (United States)

^t INSERM   (France)

^u HARVARD MEDICAL SCHOOL   (United States)

^v GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^w UMEÅ UNIVERSITY   (Sweden)

^x SAIC FREDERICK INC   (United States)

^y IMPERIAL COLLEGE LONDON   (United Kingdom)

^z AARHUS UNIVERSITY   (Denmark)

^aa CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^ab NATIONAL CANCER INSTITUTE   (United States)

^ac INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^ad BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^ae NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^af VETERANS AFFAIRS MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLTRANSFERASE;

ABO GENE; ALLELE; ARTICLE; BLOOD GROUP ABO SYSTEM; CANCER RISK; CHROMOSOME 9Q; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; FUT2 GENE; GENE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM;

ABO BLOOD-GROUP SYSTEM; ALLELES; COHORT STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; GLYCOSYLTRANSFERASES; HUMANS; ODDS RATIO; PANCREATIC NEOPLASMS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 78650323492     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-0751     Document Type: Article

References (54)

1. Reid ME, Mohandas N. Red blood cell blood group antigens: structure and function. Semin Hematol 2004;41:93-117.
2. Hakomori S. Antigen structure and genetic basis of histo-blood groups A, B and O: their changes associated with human cancer. Biochim Biophys Acta 1999;1473:247-66.
3. Wolpin BM, Chan AT, Hartge P, et al. ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst 2009;101:424-31.
4. Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, et al. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet 2009;41:986-90.
5. Risch HA, Yu H, Lu L, Kidd MS. ABO blood group, Helicobacter pylori seropositivity, and risk of pancreatic cancer: a case-control study. J Natl Cancer Inst 2010;102:502-5.
6. Wolpin BM, Kraft P, Gross M, et al. Pancreatic cancer risk and ABO blood group alleles: results from the Pancreatic Cancer Cohort Consortium. Cancer Res 2010;70:1015-23.
7. Yamamoto F, McNeill PD, Hakomori S. Human histo-blood group A2 transferase coded by A2 allele, one of the A subtypes, is characterized by a single base deletion in the coding sequence, which results in an additional domain at the carboxyl terminal. Biochem Biophys Res Commun 1992;187:366-74.
8. Storry JR, Olsson ML. The ABO blood group system revisited: a review and update. Immunohematology 2009;25:48-59.
9. Olsson ML, Chester MA. Frequent occurrence of a variant O1 gene at the blood group ABO locus. Vox Sang 1996;70:26-30.
10. Calafell F, Roubinet F, Ramirez-Soriano A, Saitou N, Bertranpetit J, Blancher A. Evolutionary dynamics of the human ABO gene. Hum Genet 2008;124:123-35.
11. Ferrer-Admetlla A, Sikora M, Laayouni H, et al. A natural history of FUT2 polymorphism in humans. Mol Biol Evol 2009;26:1993-2003.
12. Kelly RJ, Rouquier S, Giorgi D, Lennon GG, Lowe JB. Sequence and expression of a candidate for the human Secretor blood group alpha (1,2)fucosyltransferase gene (FUT2). homozygosity for an enzymeinactivating nonsense mutation commonly correlates with the nonsecretor phenotype. J Biol Chem 1995;270:4640-9.
13. Svensson L, Petersson A, Henry SM. Secretor genotyping for A385T, G428A, C571T, C628T, 685delTGG, G849A, and other mutations from a single PCR. Transfusion 2000;40:856-60.
14. Kraft P, Cox DG, Paynter RA, Hunter D, De Vivo I. Accounting for haplotype uncertainty in matched association studies: a comparison of simple and flexible techniques. Genet Epidemiol 2005;28:261-72.
15. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006;38:904-9.
16. Cochran WG. The combination of estimates from different experiments. Biometrics 1954;10:101-29.
17. Blumenfeld OO, Patnaik SK. Allelic genes of blood group antigens: a source of human mutations and cSNPs documented in the Blood Group Antigen Gene Mutation Database. Hum Mutat 2004;23:8-16.
18. Pare G, Chasman DI, Kellogg M, et al. Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women. PLoS Genet 2008;4:e1000118.
19. Yip SP. Single-tube multiplex PCR-SSCP analysis distinguishes 7 common ABO alleles and readily identifies new alleles. Blood 2000; 95:1487-92.
20. Gassner C, Schmarda A, Nussbaumer W, Schonitzer D. ABO glycosyltransferase genotyping by polymerase chain reaction using sequence-specific primers. Blood 1996;88:1852-6.
21. Aird I, Lee DR, Roberts JA. ABO blood groups and cancer of oesophagus, cancer of pancreas, and pituitary adenoma. Br Med J 1960;1 (5180):1163-6.
22. Vogel F. Controversy in human genetics. ABO blood groups and disease. Am J Hum Genet 1970;22:464-75.
23. Newell GR, Gordon JE, Monlezun AP, Horwitz JS. ABO blood groups and cancer. J Natl Cancer Inst 1974;52:1425-30.
24. Annese V, Minervini M, Gabbrielli A, Gambassi G, Manna R. ABO blood groups and cancer of the pancreas. Int J Pancreatol 1990;6:81-8.
25. Vioque J, Walker AM. Pancreatic cancer and ABO blood types: a study of cases and controls. Med Clin (Barc) 1991;96:761-4.
26. Yamamoto F, Clausen H, White T, Marken J, Hakomori S. Molecular genetic basis of the histo-blood group ABO system. Nature 1990;345:229-33.
27. Yamamoto F, Marken J, Tsuji T, White T, Clausen H, Hakomori S. Cloning and characterization of DNA complementary to human UDP-GalNAc: Fuc alpha 1-2Gal alpha 1-3GalNAc transferase (histo-blood group A transferase) mRNA. J Biol Chem 1990;265:1146-51.
28. Saitou N, Yamamoto F. Evolution of primate ABO blood group genes and their homologous genes. Mol Biol Evol 1997;14:399-411.
29. Nossent AY, Van Marion V, Van Tilburg NH, et al. von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis. J Thromb Haemost 2006;4:2556-62.
30. Gallinaro L, Cattini MG, Sztukowska M, et al. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 2008;111:3540-5.
31. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr., Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987;69:1691-5.
32. Wu O, Bayoumi N, Vickers MA, Clark P. ABO(H) blood groups and vascular disease: a systematic review and meta-analysis. J Thromb Haemost 2008;6:62-9.
33. Tregouet DA, Heath S, Saut N, et al. Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach. Blood 2009;113:5298-303.
34. Morelli VM, de Visser MC, van Tilburg NH, et al. ABO blood group genotypes, plasma von Willebrand factor levels and loading of von Willebrand factor with A and B antigens. Thromb Haemost 2007; 97:534-41.
35. Chester MA, Olsson ML. The ABO blood group gene: a locus of considerable genetic diversity. Transfus Med Rev 2001;15:177-200.
36. Hosseini-Maaf B, Hellberg A, Rodrigues MJ, Chester MA, Olsson ML. ABO exon and intron analysis in individuals with the AweakB phenotype reveals a novel O1v-A2 hybrid allele that causes four missense mutations in the A transferase. BMC Genet 2003;4:17.
37. Thuresson B, Chester MA, Storry JR, Olsson ML. ABO transcript levels in peripheral blood and erythropoietic culture show different allele-related patterns independent of the CBF/NF-Y enhancer motif and multiple novel allele-specific variations in the 5′- and 3′-noncoding regions. Transfusion 2008;48:493-504.
38. Seltsam A, Hallensleben M, Kollmann A, Blasczyk R. The nature of diversity and diversification at the ABO locus. Blood 2003;102:3035-42.
39. Lindesmith L, Moe C, Marionneau S, et al. Human susceptibility and resistance to Norwalk virus infection. Nat Med 2003;9:548-53.
40. Ikehara Y, Nishihara S, Yasutomi H, et al. Polymorphisms of two fucosyltransferase genes (Lewis and Secretor genes) involving type I Lewis antigens are associated with the presence of anti-Helicobacter pyloriIgGantibody. Cancer Epidemiol Biomarkers Prev 2001;10:971-7.
41. Ruiz-Palacios GM, Cervantes LE, Ramos P, Chavez-Munguia B, Newburg DS. Campylobacter jejuni binds intestinal H(O) antigen (Fuc alpha 1, 2Gal beta 1, 4GlcNAc), and fucosyloligosaccharides of human milk inhibit its binding and infection. J Biol Chem 2003;278:14112-20.
42. Magalhaes A, Gomes J, Ismail MN, et al. Fut2-null mice display an altered glycosylation profile and impaired BabA-mediated Helicobacter pylori adhesion to gastric mucosa. Glycobiology 2009; 19:1525-36.
43. HazraA,KraftP,SelhubJ,et al. Commonvariants of FUT2 are associated with plasma vitamin B12 levels. Nat Genet 2008;40: 1160-2.
44. Tanaka T, Scheet P, Giusti B, et al. Genome-wide association study of vitamin B6, vitamin B12, folate, and homocysteine blood concentrations. Am J Hum Genet 2009;84:477-82.
45. O'Donnell J, Boulton FE, Manning RA, Laffan MA. Genotype at the secretor blood group locus is a determinant of plasma von Willebrand factor level. Br J Haematol 2002;116:350-6.
46. Schleef M, Strobel E, Dick A, Frank J, Schramm W, Spannagl M. Relationship between ABO and Secretor genotype with plasma levels of factor VIII and von Willebrand factor in thrombosis patients and control individuals. Br J Haematol 2005;128:100-7.
47. Melzer D,PerryJR,Hernandez D,et al. Agenome-wide association study identifies protein quantitative trait loci (pQTLs). Jt 2008;4:e1000072.
48. Paterson AD, Lopes-Virella MF, Waggott D, et al. Genome-wide association identifies the ABO blood group as a major locus associated with serum levels of soluble E-selectin. Arterioscler Thromb Vasc Biol 2009;29:1958-67.
49. Qi L, Cornelis MC, Kraft P, et al. Genetic variants in ABO blood group region, plasma soluble E-selectin levels and risk of type 2 diabetes. Hum Mol Genet 2010;19:1856-62.
50. Barbalic M, Dupuis J, Dehghan A, et al. Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels. Hum Mol Genet 2010;19:1863-72.
51. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006;20:1218-49.
52. Wacholder S, Rothman N, Caporaso N. Population stratification in epidemiologic studies of common genetic variants and cancer: quantification of bias. J Natl Cancer Inst 2000;92:1151-8.
53. Shibuya K, Mathers CD, Boschi-Pinto C, Lopez AD, Murray CJ. Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC Cancer 2002;2:37.
54. Available from: http://www.whiscience.org/publications/WHI-investigators- shortlist.pdf.